Browsing by Author "Shah, Nishant P"

Now showing 1 - 4 of 4
  • Thumbnail Image
    ItemOpen Access
    Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.
    (American journal of preventive cardiology, 2023-03) Khedagi, Apurva; Hoke, Cara; Kelsey, Michelle; Coviello, Andrea; Jones, W Schuyler; Jackson, Larry R; Patel, Manesh R; McGarrah, Rob W; Pagidipati, Neha J; Shah, Nishant P
    Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Among the most prominent disparities within cardiovascular disease prevention are with the use and distribution of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. Several landmark trials have demonstrated the efficacy of these novel agents, not only in cardiovascular disease prevention among those with diabetes, but also in heart failure and chronic kidney disease. However, the use of these agents remains limited by disparities in certain racial/ethnic, sex, and socioeconomic groups. This review works to highlight and understand these differences on the use and prescribing patterns of pivotal agents in cardiovascular disease prevention, SGLT-2 inhibitors and GLP-1 agonists. Our aim is to enrich understanding and to inspire efforts to end disparities in cardiovascular morbidity and mortality due to race, sex and income inequality.
  • Thumbnail Image
    ItemOpen Access
    Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.
    (JACC. CardioOncology, 2022-06-21) Zullig, Leah L; Sung, Anthony D; Khouri, Michel G; Jazowski, Shelley; Shah, Nishant P; Sitlinger, Andrea; Blalock, Dan V; Whitney, Colette; Kikuchi, Robin; Bosworth, Hayden B; Crowley, Matthew J; Goldstein, Karen M; Klem, Igor; Oeffinger, Kevin C; Dent, Susan
    There are nearly 17 million cancer survivors in the United States, including those who are currently receiving cancer therapy with curative intent and expected to be long-term survivors, as well as those with chronic cancers such as metastatic disease or chronic lymphocytic leukemia, who will receive cancer therapy for many years. Current clinical practice guidelines focus on lifestyle interventions, such as exercise and healthy eating habits, but generally do not address management strategies for clinicians or strategies to increase adherence to medications. We discuss 3 cardiometabolic comorbidities among cancer survivors and present the prevalence of comorbidities prior to a cancer diagnosis, treatment of comorbidities during cancer therapy, and management considerations of comorbidities in long-term cancer survivors or those on chronic cancer therapy. Approaches to support medication adherence and potential methods to enhance a team approach to optimize care of the individual with cancer across the continuum of disease are discussed.
  • Thumbnail Image
    ItemOpen Access
    Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
    (Journal of clinical medicine, 2020-03-25) Kikuchi, Robin; Shah, Nishant P; Dent, Susan F
    Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exposed to these agents. Novel cancer therapies have led to significant improvements in clinical outcomes for breast cancer patients. In this article, we review the current literature on assessing cardiovascular risk of breast cancer therapies and discuss strategies (including pharmacological and lifestyle interventions) to prevent cardiovascular toxicity.
  • Thumbnail Image
    ItemOpen Access
    The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post-Hoc Analysis of ACCELERATE.
    (Diabetes care, 2019-12-05) Shah, Nishant P; Wang, Qiuqing; Wolski, Katherine E; Cho, Leslie; McErlean, Ellen; Ruotolo, Giacomo; Weerakkody, Govinda; Riesmeyer, Jeffrey S; Nicholls, Stephen J; Lincoff, A Michael; Nissen, Steven E; Menon, Venu